Biosafety assessment of engineered CCL20 locked dimers in vivo Authors: Donovan Drouillard, Maria Poimenidou, Marissa Davies, Donna McAllister, William R Clarke, Samuel T Hwang, Francis C Peterson, Brian F Volkman, Michael B Dwinell Published: 2025 ABSTRACT AbstractImmune dysregulation by aberrant chemokine production underlies many diseases. Targeting chemokine receptors with small molecule inverse agonists, antagonists, or neutralizing antibodies has proven challenging due to non-specific effects and receptor upregulation. Locked dimers of chemokines, generated via cysteine substitutions to produce constitutively homodimeric molecules, offer a promising alternative for receptor-specific inhibition. This study evaluates the in vivo safety and dosing of an engineered CCL20 locked dimer (CCL20LD), which selectively binds CCR6 without inducing chemotaxis. The antagonist-like properties of CCL20LD make it a potential therapeutic for CCL20-CCR6 driven diseases. Daily 14-day subcutaneous administration of CCL20LD at doses previously shown to be therapeutically effective in preclinical models of psoriasis or psoriatic arthritis did not result in weight loss or immune suppression. CCL20LD administration had little to no effects on the complete blood count with differential, comprehensive metabolic panel, urinalysis, organ weights, or bone marrow progenitors. At single cell resolution, doses near 7.5mg/kg/day modestly disrupted T cell dependent B cell activation. While splenomegaly due to extramedullary hematopoiesis was observed at the highest tested dose, serum cytokine levels were largely unchanged. Combined, these findings indicate that selective targeting of CCR6 with an engineered CCL20 dimer is broadly safe in vivo, exhibiting a wide therapeutic window with minimal adverse or immunomodulatory effects.Supplementary InformationThe online version contains supplementary material available at 10.1007/s10565-025-10131-6.Keywords: CCR6, CCL20, Recombinant chemokine, Safety pharmacology Introduction The cytokine interleukin-17 (IL-17) plays a central role in the pathogenesis of numerous autoimmune and inflammatory diseases and is primarily produced by a subset of CD4 + T helper cells known as Th17 cells (Park et al. 2005). These non-canonical helper T cells are characterized by expression of the transcription factor RAR-related orphan receptor gamma t (RORγt) and are responsiveness to IL-23 signaling (Mortier et al. 2023). In addition to Th17 cells, IL-17 is also produced by subsets of CD8 + T cells, γδ T cells, innate lymphoid cells (ILCs), natural killer (NK) cells, invariant NK T cells, and mucosal-associated invariant T cells, underscoring its broad role in immune regulation (Huangfu et al. 2023). IL-17 contributes significantly to host defense, but its dysregulation is implicated in chronic inflammatory conditions such as rheumatoid arthritis, psoriasis, psoriatic arthritis, inflammatory bowel disease (IBD) and chronic graft versus host disease (McGeachy et al. 2019). In cancer, IL-17 exhibits context-dependent roles, either promoting tumor growth, angiogenesis, and metastasis or contributing to anti-tumor immunity (Zhang et al. 2024). IL-17 is also involved in protective immunity in response to certain infections, although it may exacerbate infectious processes if dysregulated (Sahu et al. 2021). Current therapies targeting Th17-driven inflammation, including TNF inhibitors, JAK inhibitors, and IL-17/IL-23 biologics (e.g., secukinumab, ixekizumab, brodalumab, and bimekizumab), have shown clinical efficacy but are often limited by systematic immunosuppression, increased infection risk, paradoxical inflammatory responses such as new-onset IBD , and the development of anti-drug antibodies resulting in loss of efficacy (Fauny et al. 2020; Hoisnard et al. 2022; Li et al. 2021; Ruggiero et al. 2023; Saran et al. 2025; Wang et al. 2023). Small molecule inhibitors can transiently suppress IL-17 production but have been hampered by off-target toxicity and poor clinical success (Zeng et al. 2023). Thus, there remains a pressing need for new immunotherapies that can selectively modulate pathogenic Th17 cell function without compromising immune protection. Chemokine signaling is a critical driver of immune dysregulation in inflammatory and autoimmune diseases. The CCR6-CCL20 chemokine signaling axis has emerged as a pivotal pathway in Th17 cell migration and tissue-specific inflammation and much like IL-17, CCR6-CCL20 plays a central role in promoting disease progression in psoriasis, rheumatoid arthritis, and IBD (Cochez et al. 2017; Furue et al. 2020; Lee and Korner 2014; Shi et al. 2021; Skovdahl et al. 2015). CCL20, also known as liver and activation-regulated chemokine, macrophage inflammatory protein-3α, or Exodus-1 (Schutyser et al. 2003), is expressed across a variety of tissues and cell types, including the cervix, prostate, thymus, skin, colon, liver, lymph nodes, endothelial cells, epithelial cells, neutrophils, Th17 cells, keratinocytes, and macrophages (Kadomoto et al. 2020; Nandi et al. 2014; Scapini et al. 2001; Yamazaki et al. 2008). CCL20’s expression is strongly upregulated by pro-inflammatory stimuli such as TNF, IL-1β, and IL-17A.(Meitei et al. 2021) Functionally, CCL20 directs the recruitment of CCR6 + Th17 cells, regulatory T cells (Tregs), macrophages, and dendritic cells to sites of inflammation (Meitei et al. 2021). CCR6 is a 7 transmembrane G protein-coupled receptor (GPCR) that binds exclusively to CCL20, a notable exception to the promiscuity observed among most chemokine receptors (Schutyser et al. 2003). It is constitutively expressed in immune cells located in mucosal tissues, including the intestinal and lung mucosa, as well as in lymphoid and non-lymphoid organs such as lymph nodes, spleen, appendix, pancreas, and thymus (Baba et al. 1997; Cook et al. 2000; Greaves et al. 1997; Liao et al. 1997; Zaballos et al. 1996). CCR6 expression levels vary based on the cell type, maturation, and differentiation state (Annunziato et al. 2007; Kondo et al. 2007; Lee and Korner 2019; Schutyser et al. 2003). The CCL20-CCR6 axis orchestrates immune cell trafficking to inflamed sites and has been implicated in mucosal immunity, tissue inflammation, cancer progression, and autoimmune diseases, particularly in skin and mucosal surfaces (Furue et al. 2020). Despite the clinical relevance of CCR6 in a wide array of disease contexts, therapeutic targeting of chemokine receptors remains challenging (Lorente et al. 2025). Although GPCRs represent one of the most successful drug target classes, efforts to develop small-molecule inhibitors of chemokine receptors have often failed due to issues of specificity, receptor redundancy, and on-target toxicity (Solari et al. 2015). Alternative strategies, including monoclonal antibodies, nanobodies, or other biologic drug candidates are currently in development (Schlimgen et al. 2024; Schlimgen and Volkman 2025). To address these limitations, our group has pioneered the design, development, and efficacy testing of recombinant chemokines bioengineered into their naturally occurring dimer structure in cancer and autoimmune diseases (Shi et al. 2021),(Drouillard et al. 2025; Drury et al. 2011; Getschman et al. 2017; Shi et al. 2023). Our prior work targeting CCR6 has investigated the therapeutic potential of a novel engineered compound, CCL20 locked dimer (CCL20LD) (Getschman et al. 2017; Shi et al. 2021, 2023). Generated by a single-atom substitution in the natural chemokine molecule, CCL20LD selectively inhibits CCR6 by acting as a partial agonist, inducing GPCR activation while minimizing chemotactic activity. Thus, CCL20LD effectively blocks CCR6-mediated immune cell trafficking and reducing symptoms of disease in animal models without disrupting other chemokine signaling pathways (Getschman et al. 2017; Shi et al. 2021). We have demonstrated CCL20LD efficacy in reducing psoriatic inflammation, decreasing IL-17A and IL-22 signaling, and alleviating joint and skin inflammation in IL-23-mediated murine disease models (Shi et al. 2021). These findings support the translational potential of targeting the CCR6-CCL20 axis to ameliorate Th17 autoimmune diseases by preventing the trafficking of disease-promoting cells into susceptible tissues. To investigate CCL20LD as a lead candidate for further development, we completed an initial safety profile of CCL20LD in mice. Given CCR6’s role in mucosal immunity, Peyer’s patch formation, and immune cell homeostasis, it is essential to evaluate the compound’s potential for immunosuppression or other adverse effects. The current study profiled the in vivo safety of CCL20LD, focusing on its systemic, hematologic, and immune effects across a wide dose range and varying dosing schedules. Here, we report findings from a comprehensive safety study of CCL20LD in mice, including assessments of injection site reactions, immune cell populations, clinical chemistry, hematology, organ-specific effects, serum cytokine levels, and single-cell RNA analysis of splenocytes from treated mice. The results demonstrate that CCL20LD was well tolerated, with a large therapeutic window and minimal side effects or systemic immune suppressive functions at therapeutically relevant doses. These findings provide foundational evidence for the safety and therapeutic potential of CCL20LD as a biologic protein for CCR6-mediated diseases. Results Systemic and local macroscopic observations As our prior work demonstrated CCL20LD efficacy in two preclinical models of Th17-mediated autoimmune disease, we initiated a series of biosafety studies to support the translational potential of the bioengineered locked dimer. The initial CCL20LD biosafety screen was completed by Charles River Laboratories, an independent research organization. For this assessment, 10-week-old male and female CD1 mice (n = 10 per sex) were administered daily subcutaneous injections of vehicle, sterile PBS, or CCL20LD at 2.5, 7.5, or 22.5 mg/kg/day for 14 consecutive days with close clinical monitoring throughout the study period. Our prior work showed pathophysiologic benefits at 1 mg/kg/day and 5 mg/kg/day following intraperitoneal administration in B10 murine models of psoriatic arthritis and psoriasiform dermatitis, respectively (Shi et al. 2021). The chosen concentrations for this initial safety study represent a therapeutically relevant dose, a mid-range dose approximately 1.5-to-7 times higher, and a high dose approximately 4-to-22.5 times the therapeutic concentration, using an outbred CD1 mouse strain. Daily administration of 2.5 mg/kg and the 7.5 mg/kg dose was well tolerated, with no overt impact on survival (Fig. 1A, B) or body weight (Fig. 1C, D). At the highest dose (22.5 mg/kg), three of twenty animals (two male, one female) died or were humanely euthanized (Fig. 1A, B). No cause of death was identified by a veterinary pathologist during necropsy. CCL20LD is safe at high doses and with moderate injection site reactions. (A) Survival of CD-1 male and (B) female mice given various doses of CCL20LD. (C) Body weight over time in male and (D) female mice. (E) Presence of injection site scabbing in male and (F) female mice. N = 10 mice per dosage for each sex Injection site reactions were observed in two mice at the 22.5mg/kg dose. One male mouse had a serocellular crust at the injection site while one female mouse had moderate mixed cell inflammation. Injection site scabbing was monitored over time (Fig. 1E, F). To account for the effects of repeated injections of phosphate buffered saline, used as the diluent and vehicle control, which is known to cause injection site pain (Cohen et al. 2019), a multiple logistic regression was performed. When performing this analysis in males only, day and dose had a minor but significant > 1 odds ratio indicating a beneficial effect, or less scabbing (odds ratios with 95% confidence interval of 1.022—1.162 and 1.017–1.123, respectively). When performing this analysis in females only, a similar pattern was found (odds ratios of 1.004–1.138 and 1.023–1.138). However, a minor but significant < 1 odds ratio (more scabbing) was found when accounting for day*dose (0.9774–0.9888 in males and 0.9851–0.9962 in females). When adjusting the regression to include both sexes, the female sex had a significant beneficial odds ratio of 1.107–1.919 while day*dose maintained a significant but minor detrimental odds ratio of 0.9836–0.9912. These data suggest that prolonged, high dose CCL20LD injections may contribute to injection site scabbing but the largest effect observed was due to sex, in line with the literature observing faster wound healing in female mice (Rowland et al. 2023). Hematologic, clinical chemistry, and urinalysis assessment Hematological parameters were analyzed through blood collected from the venae cavae of five mice per group following euthanasia by carbon dioxide inhalation on day 15. Notably, CCL20LD had no significant impact on total red blood cell count, hemoglobin, hematocrit, mean corpuscular volume, mean corpuscular hemoglobin, red blood cell distribution width, or platelet count in either males or female mice across all doses tested (Supplementary Fig. 1A-N). Reticulocyte counts increased by 33% in male mice receiving the highest dose (22.5 mg/kg/day dose), but the observed values still fall within previously reported ranges for healthy CD1 mice (Coman et al. 2018). No corresponding changes were observed in female mice (Fig. 2A, B). Consistent with the variable changes in reticulocytes, clinical chemistry analyses indicated no significant changes in the liver enzyme alanine aminotransferase (ALT) (Fig. 2C, D), but a modest statistical increase in aspartate aminotransferase (AST) measured in female mice at a single treatment dose (Fig. 2E, F). In contrast, male mice but not female mice, showed a 35% decrease in alkaline phosphatase (ALP) at the maximal 22.5 mg/kg/day dose (Fig. 2G, H). When assessing the results of the three tested liver enzymes together, the pattern observed suggests an extrahepatic cause of the small shifts in liver enzyme levels (Oh et al. 2017). Despite statistical significance, these clinical chemistry changes demonstrate limited clinically relevant damage, as the observed values remained within the reference range for CD1 mice and thus likely reflect normal variability between mice (Laboratories, CR, 2012). Ultimately, clinical chemistry evaluation revealed no changes compared to control mice in the AST/ALT, the De Ritis, ratio (Supplementary Fig. 2A, B). Hematology and clinical chemistry of mice treated daily with CCL20LD. (A, B) Reticulocyte levels relative to red blood cells. (C) Alanine transaminase (ALT) levels (U/L) in male and (D) female mice. (E, F) Aspartate aminotransferase (AST) levels. (G, H) Alkaline phosphatase (ALP) levels. (I, J) Resting blood glucose levels (mg/dL). (K, L) Sodium levels (mEq/L). (M, N) Bicarbonate levels as a measure of carbon dioxide (CO2) levels. * denotes P ≤ 0.05 by one-way Anova with Tukey’s multiple comparisons test. N = 3–5 mice per dosage for each sex Key markers of tissue damage demonstrated no measurable changes with CCL20LD administration. Notably, total bilirubin (TBIL), creatinine (CREAT), blood glucose, cholesterol, total protein, albumin, globulin, the albumin/globulin ratio, calcium, phosphorus, sodium, potassium, or chloride levels did not change in either males or females (Fig. 2I-L, Supplementary Fig. 2C-P, and Supplementary Fig. 3A-H). Triglyceride levels increased two-fold at a single dose of chemokine in female but not male mice (Supplementary Fig. 3I, J). In contrast, male mice but not females, had a 20% decrease in blood urea nitrogen (BUN) solely at the highest 22.5 mg/kg/day dose (Supplementary Fig. 3K, L). Lastly, blood bicarbonate levels were elevated by ~ 25% at 2.5 and 7.5mg/kg/day in female mice with no comparable change measured in male mice (Fig. 2M-N). As bicarbonate levels did not increase further at higher doses and other electrolytes remained stable, these changes are unlikely to reflect CCL20LD-induced metabolic alkalosis, a clinical finding that will require future analysis of arterial blood gas (Emmett 2020). Urinalysis revealed no significant changes in urine volume, glucose or ketone levels, specific gravity, pH, or protein levels (Supplementary Fig. 4A-L). The absence of abnormalities in both urinary and serum electrolyte parameters indicate that CCL20LD has negligible impact on renal function. Effects on organ weights During necropsy, organs were collected and weighed, with paired organs assessed together. For each tissues, absolute weights, weight relative to body weight (%bw), and weight relative to the brain weight (%br) were calculated. No significant differences were seen in the absolute weight, %bw, or %br of the adrenals, brain, heart, kidneys, liver/gallbladder, or thymus in either sex at any dose (Supplementary Fig. 5A-L). Similarly, no sex-specific changes were detected in the testes, epididymis, uterus/cervix, or ovaries at any dose (Supplementary Fig. 5M-P). However, there was significantly increased absolute spleen weight, spleen %br, and spleen %bw at the highest dose tested in both male and female mice (Fig. 3A-F). Microscopic examination of the spleens revealed extramedullary hematopoiesis in mice receiving ≥ 7.5 mg/kg/day of CCL20LD. This was characterized by expansion of erythroid and megakaryocytic precursor populations within the splenic red pulp. Taken together with the observed increases in circulating reticulocytes and the absence of other major hematologic abnormalities, these findings support a model in which CCL20D induces splenic extramedullary hematopoiesis. Splenomegaly following 14-day daily CCL20LD administration is consistent with previous observations from preclinical and clinical studies of chemokine receptor inhibitors targeting CXCR4 and CXCR1/2 (Prajapati et al. 2023). Spleen size after two weeks of daily CCL20LD treatment. (A) Spleen mass (in grams), (B) spleen weight relative to body weight (%bw) and (C) spleen weight relative to brain weight (%bw) in male and (D-F) female mice. * denotes P ≤ 0.05 by one-way Anova with Tukey’s multiple comparisons test. N = 10 mice per dosage for each sex Effects on the immune system To assess the potential for CCL20LD to broadly influence the immune system, we conducted a comprehensive analysis of peripheral blood immune cell populations using the a separate cohort of mice to that analyzed for the hematological and clinical chemistry analyses. No significant changes in total circulating white blood cell counts were observed at any dose group in either sex (Fig. 4A, B). However, male mice receiving the highest dose of 22.5 mg/kg/day exhibited an approximate two-fold increase in both the percentage and absolute number of circulating neutrophils, a CCR6-negative granulocytic population, suggesting a potential indirect mechanism underlying this neutrophilia (Fig. 4C). In contrast, female mice showed a more modest 1.5-fold increase in neutrophil percentage, with minimal changes in absolute neutrophil counts (Fig. 4D). At the highest dose of 22.5 mg/kg/day, male but not female mice, exhibited a ~ 15% decline in circulating lymphocyte levels (Fig. 4E, F). Monocyte (Fig. 4G, H) and eosinophil levels (Supplementary Fig. 6A, B) remained unchanged across all treatment groups in both sexes. Additionally, male mice treated with 22.5 mg/kg/day showed a five-fold increase in basophils, with the measured increase remaining within the reference range (Fig. 4I, J) (Coman et al. 2018). A similar five-fold increase in large unstained cells (LUCs) was observed in male but not female mice (Supplementary Fig. 6C, D). While LUCs are a standard hematology readout and may be associated with inflammatory responses, they represent a broad category of cells and lack specificity; thus LUC elevations are infrequently used to guide clinical decision-making (Buttarello and Plebani 2008; Rezan Kocak Ulucakoy et al. 2025; Thirup 1999). Changes in circulating leukocytes following daily CCL20LD administration. (A) Total circulating white blood cells (WBC) taken from vena cava blood post-carbon dioxide inhalation following two-week treatment with CCL20LD in males and (B) females. (C, D) Relative neutrophil levels. (E, F) Relative lymphocyte levels. (G, H) Relative monocyte levels. (I, J) Relative basophil levels. * denotes P ≤ 0.05 by one-way Anova with Tukey’s multiple comparisons test. N = 3–5 mice per dosage for each sex Changes in splenocytes Flow cytometry, serum cytokine levels, and transcriptomic sequencing were used to further investigate CCL20LD’s impact on the immune system. For these studies we interrogated six-week-old C57BL/6J male mice as a more common preclinical model of immune function and toxicology. Previous studies performed in C57BL/6 mice demonstrated that CCL20LD has a half-life of about six hours with similar serum concentrations obtained following intravenous, subcutaneous, or intraperitoneal administrationof CCL20LD (Wu et al. 2023). We modified the treatment regimen so that mice were treated intraperitoneally with vehicle (sterile PBS), 100 μg CCL20LD, or 200 μg CCL20LD every other day (QOD) for 21 days, corresponding to a ~ 4 and 8 mg/kg/QOD, respectively. These doses and schedule reflect prior studies in murine models of psoriasis and colon cancer, while representing reduced frequency and lower cumulative exposure compared to the daily dosing regimens used in the Charles River studies. Subcutaneous injections were used to study the complete toxicology as that is a more likely route of administration for patients, while intraperitoneal injections were chosen to examine the systemic impact on the immune system. Under this dosing schedule, no significant changes in spleen weight were observed at either dose, suggesting that therapeutic levels of CCL20D administered intermittently do not induce detectable extramedullary hematopoiesis (Supplementary Fig. 7A). As shown in Fig. 5A and Supplementary Fig. 7B-O, relative to the CD45 + population in each spleen, no frequency changes were measured in total CD3 + T cells, or the CD4 + T cells, CD8 + T cells, CD4/CD8 ratio, CD8 + central memory (CD44 + CD62L +), CD4 + central memory, CD4 + effector memory (CD44 + CD62L-), CD8 + effector memory, or naïve CD8 + (CD44- CD62L +) T cell subsets. Similarly there was no impact of CCL20LD on B cell (CD3- CD19 +), myeloid cell (CD3- CD11b +), NK cell (CD3- NK1.1 +), neutrophil (CD11b + Ly6G +), Ly6C + macrophage (CD11b + CD11c- F4/80 +), or dendritic cell (CD11b + CD11c + MHC class II high) cell populations in the spleens of treated mice. While there was a minor increase in Ly6C- macrophages in mice treated with 200 µg CCL20LD, naïve CD4 + T cells were modestly reduced by 10% (Supplementary Fig. 7P, Fig. 5B). While we did not test for differences in CCL20LD metabolism between CD1 and C57BL/6 mice, comparing results from the two strains suggest that alternate-day administration of CCL20LD at 8 mg/kg/QOD was largely well tolerated, with minimal immune suppressive or toxic effects. CCL20LD effects on circulating naïve T cell levels and bone marrow progenitor populations. (A) The frequency of CD3 + T cells in the spleen relative to CD45 + cells in C57/BL6 mice given either vehicle, 100 μg or 200 μg every other day for 21 days. (B) Naïve CD4 + T cell levels relative to total CD4 + T cells. (C) The frequency of CD4 + and (D) CD8 + T cells in the bone marrow (BM) relative to total CD45 + cells. (E) The frequency of lineage (CD3- CD45R- CD11b- Ter-119- Ly6G-) negative cells in the bone marrow relative to total live cells. (F) The frequency of hematopoietic stem cells (HSC LIN- Sca-1 + cKIT +), (G) common myeloid progenitor cells (CMP LIN- Sca-1- cKIT + CD16/32- CD34 +), (H) common lymphoid progenitor cells (CLP LIN- SCA-1 + cKIT + CD127 +), (I) granulocyte-monocyte progenitor cells (GMP LIN- Sca-1- cKIT + CD16/32 + CD34 +), and (J) megakaryocytic-erythroid progenitor cells (MEP LIN- Sca-1- cKIT + CD16/32- CD34-) relative to the lineage negative cells in the bone marrow. * denotes P ≤ 0.05 by one-way Anova with Tukey’s multiple comparisons test. N = 10 male mice per dosage To complement the cellular analysis, we completed an unbiased profiling of serum cytokine levels using a multiplex Luminex assay. Serum was obtained from vehicle and 200 μg/QOD CCL20LD treated mice at days 7, 14, and 20. Although no cytokines were significantly altered, modest trends were observed. At day 7, effector cytokines involved in CD4 + T cell function such as IL-17, IL-10, IL-4, and IFNγ were decreased in CCL20LD treated mice (Supplementary Fig. 8A). These reductions persisted through day 14, although several cytokines fell below the detectable limit in both groups (Supplementary Fig. 8B). It is likely that more robust changes in the CD4 + T cell effector cytokines would be detectable in the context of inflammation rather in immunologically naïve mice. At day 20, trending increases were seen in G-CSF and IL-3 in the CCL20LD treated mice (Supplementary Fig. 8C). Both G-CSF and IL-3 are involved in hematopoiesis and erythropoiesis, suggesting they may contribute to the splenic expansion and extramedullary hematopoiesis noted in higher-dose CCL20LD-treated mice (Bernitz et al. 2017; Ihle 1992). Changes in bone marrow CXCR4 or CXCR1/2 inhibitor-associated splenomegaly was a result of immune mobilization from the bone marrow (Corporation 2008; Prajapati et al. 2023). Given CCL20LD similarly provoked splenomegaly, the next studies examined CCL20LD’s effect on immune precursors. Bone marrow was harvested from the femurs and tibias of the mice described in Fig. 5A and processed for flow cytometry. While CCL20/CCR6 axis has been implicated in pathologic marrow remodeling and trabecular bone function, its roles in bone marrow immune homeostasis remains poorly defined (Doucet et al. 2016; Giuliani et al. 2008). The impacts seen on the immune populations in the bone marrow matched the observations recorded from the experiments performed at Charles River Laboratories examining circulating leukocytes. Thus, levels of T cells were decreased by 25% in both CD4 + and CD8 + lineages (Fig. 5C, D) with no overall change in the CD4/CD8 ratio (Supplementary Fig. 9A). Within those populations, the naïve portion decreased while the effector memory and central memory populations increased (Supplementary Fig. 9B-G). B cells decreased 30% as well, but NK cells did not change, suggesting CCL20LD’s effects were not a global change in lymphocyte populations (Supplementary Fig. 9H, I). Conversely, myeloid and neutrophil populations increased marginally while dendritic cells and Ly6C +/Ly6C- macrophage populations remained unchanged (Supplementary Fig. 9J-N). A separate flow cytometry panel was performed on the same mice to characterize progenitor cell populations in the bone marrow to examine if CCL20LD affected immune precursors. No changes were detected in the lineage (LIN) negative (CD3-, CD45R-, CD11b-, Ter-119-, Ly6G-) population relative to the total live cells (Fig. 5E). Relative to the total LIN- populations, there was a 30% increase in LIN-, Sca-1 +, cKIT + hematopoietic stem cells (HSC), and an 80% increase in LIN-, Sca-1-, cKIT +, CD16/32-, CD34 + common myeloid progenitors (CMP) (Fig. 5F, G). Other progenitor populations did not change in response to CCL20LD, including LIN-, SCA-1 +, cKIT +, CD127 + common lymphoid progenitors (CLP), LIN-, Sca-1-, cKIT +, CD16/32 +, CD34 + granulocyte-monocyte progenitors (GMP), or LIN-, Sca-1-, cKIT +, CD16/32-, CD34- megakaryocytic-erythroid progenitor cells (MEP) (Fig. 5H-J). The increase in HSCs further supports the extramedullary hematopoiesis measured in the spleen and suggests a potential mechanism reflecting HSC mobilization rather than a response to inflammatory signals or a pathologic condition (Rivera-Torruco et al. 2024). However, as HSCs do not undergo chemotaxis in response to wild-type CCL20 and further studies are needed to determine the mechanism(s) by which CCL20LD modulated HSC populations (Wright et al. 2002). Single cell RNA analysis of CCL20LD treated mice Single cell RNA sequencing was performed on splenocytes from control and 200 μg/QOD CCL20LD treated mice from the previous C57BL/6 mouse experiments to better understand CCL20LD’s effect on secondary lymphoid organs. Pseudobulk analysis of total splenocytes between the control and treated mice expectedly returned elevated expression of gene pathways involved in cell proliferation in the CCL20LD treated mice, consistent with the measured splenomegaly and extramedullary hematopoiesis (Fig. 6A). Analysis of the immune populations present revealed a relative increase in neutrophils and macrophages, similar to the analysis of whole blood peripheral blood mononuclear cells and flow cytometry of splenocytes, respectively (Fig. 6B). A smaller relative increase was seen in Treg and dendritic cell populations. However, a 25% relative decrease was seen in B cells, with CCL20LD predominately reducing the frequency of follicular B cells and increasing the frequency of marginal zone B cells (Fig. 6C). In line with these findings, B cells were the highest CCR6 expressing cells among splenocytes (Fig. 6D). To further characterize these differences, pseudobulk analysis was performed on follicular B cells from vehicle- and CCL20LD-treated animals (Fig. 6E). Upregulated genes in the treated follicular B cells, such as Il4i1, Tlr9, and Irf5, are indicative of a T cell-independent mechanism of B cell differentiation into IgM-secreting cells (Bod et al. 2018; De et al. 2017; Jiang et al. 2007). While follicular B cells are canonically not thought to play a role in the T cell-independent B cell response, previous studies have shown they contribute to an T cell-independent antibody response (Daly et al. 2020; Swanson et al. 2010). Comparatively, upregulated genes in the control mice included Zbtb20, Irf4, and Tcf4 (E2-2, ITF-2), indicative of the traditional T cell-dependent B cell activation (Chevrier et al. 2014; Wohner et al. 2016). These findings align with prior studies showing that CCR6 is required for effective secondary lymphoid organ follicle formation (McDonald et al. 2007), antigen-driven B cell differentiation (Krzysiek et al. 2000), and T follicular helper localization (Bastow et al. 2022). Reduced follicular B cell abundance and altered transcriptional programming in CCL20LD-treated mice are consistent with observations in CCR6 knockout models, which exhibit reduced T cell-dependent B cell activation and generation of B cell memory (Elgueta et al. 2015). Cumulatively, these data from spleen and bone marrow profiling indicate that CCL20LD was not broadly suppressing the immune system. Importantly, CCL20LD did not reduce any progenitor populations in the marrow, indicating that hematopoietic capacity remains functionally intact (Schoedel et al. 2016). CCL20LD impact on memory B cells at single cell resolution. (A) Biological process gene ontology terms for the differentially expressed genes by pseudobulk analysis in control and CCL20LD-treated spleens. (B) The frequency of the detected immune populations relative to total cells. * denotes P ≤ 0.05 by multiple T tests. (C) The frequency of the detected B cell subsets relative to total B cells. * denotes P ≤ 0.05 by multiple T tests. (D) CCR6 expression in all identified cell populations and B cell subsets in all mice. (E) Differentially expressed genes in follicular B cells from CCL20LD-treated (right) and control (left) treated mice. Red dots indicate genes with adjusted P value (by pseudobulk test) ≤ 0.005 and log2FC ≥ 1. Blue dots indicate genes with adjusted P ≤ 0.005 but not log2FC ≥ 1. Green dots indicate genes with log2FC ≥ 1 but not adjusted P value ≤ 0.005. N = 4 male mice per dosage Discussion Our prior reports indicate that recombinant CCL20LD potently decreases disease and Th17 T cell infiltration in two separate skin disease models (Getschman et al. 2017; Shi et al. 2021). In order to translate CCL20LD for use as a human therapeutic, we completed two independent biosafety and immune profiling studies. Studies at Charles River and in our lab demonstrated that doses of CCL20LD used to therapeutically treat psoriasis or psoriatic arthritis in mice exhibited minimal side effects, with a relatively broad therapeutic window. At the lowest dose tested, the only side effect observed was injection site scabbing. At higher doses, in excess of 20 mg/kg/day, CCL20LD modestly impacted immune homeostasis. The relatively small change in spleen size mirrors reports from CXCR4 or CXCR1/2 inhibitor studies and likely reflects extramedullary hematopoiesis as suggested by elevated reticulocyte counts and levels of hematopoietic stem cells in the bone marrow. Despite these findings, no significant increases in circulating red blood cells, which would indicate polycythemia, were observed. Megakaryocyte-erythroid progenitor levels in the bone marrow did not decrease, further suggesting the extramedullary hematopoiesis was not in response to a failure of erythropoiesis in the marrow. A summary of our findings can be seen in Supplementary Table 1 and is illustrated in Fig. 7. Cumulatively, these data indicate that CCL20LD is broadly safe, with limited tissue toxicity and no measurable suppression of the immune system in two strains of mice over daily or every other day dosing regimens. Schematic diagram illustrating the broad safety profile of engineered recombinant CCL20 locked dimers (CCL20LD) A distinct immunological change observed in both the spleen and bone marrow of mice treated with CCL20LD was a decrease in naïve T cell populations coupled with an increase in effector T cell populations. While this shift could reflect increase immune activation, no clinical signs of inflammation were observed (Shchukina et al. 2023). Further, while traditional lab tests to assess inflammation, such as measuring C-reactive protein or erythrocyte sedimentation rate were not completed, surrogate lab values to measure inflammation such as hemoglobin or total white blood cell counts did not change (Weiss et al. 2019). Lastly, these studies examined the effects of CCL20LD in healthy mice. Clinically, CCL20LD is envisioned as biologic immunotherapy that would be administered for Th17-predominant autoimmune conditions with high baseline levels of inflammation. Our published data indicate that CCL20LD potently inhibited the infiltration of epidermal T cells into the inflamed dermis in murine models. Future studies interrogating the total T cell and B cell populations in mice with acute or chronic inflammation are needed to ascertain the breadth and extent of CCL20LDs influence during ongoing immune responses. Impaired memory B cell formation measured after disruption of the CCL20-CCR6 axis with the CCL20LD partial agonist mirrors immune modulation characterized in CCR6 knockout mice (Reimer et al. 2017). The similarities between CCR6 knockout mice and CCL20LD treated mice provides a further layer of specificity for the dimers safety and suggests further mechanistic studies are needed to determine the extent of memory B cell dysfunction due to CCR6/CCL20 disruption. While this change in memory B cells may be detrimental for T cell-dependent B cell responses, such as with vaccination in healthy individuals, it may prove beneficial in autoimmune disease driven by self-reactive memory B cells such as systemic lupus erythematosus, rheumatoid arthritis, and multiple sclerosis (Comi et al. 2021; Dorner and Lipsky 2024; Kristyanto et al. 2020). Moreover, this mechanism could make CCL20LD even more effective in alleviating rheumatoid arthritis or other autoimmune diseases by concomitantly targeting both Th17 and memory B cell mechanisms of pathogenesis (Reijm et al. 2023). While not examined here, the elevation of macrophage and neutrophil frequencies in healthy mice may reflect a compensatory innate immune mechanism for the diminishment in adaptive memory B cell populations. Current treatments for moderate to severe cases of inflammatory diseases, such as psoriasis and IBD, include TNF inhibitors or JAK inhibitors that cause broad immunosuppression with significant side effects (Hoisnard et al. 2022; Li et al. 2021). While mild immunosuppression was observed with CCL20LD, this occurred at doses far above those required to achieve therapeutic effects in psoriasis or psoriatic arthritis (Getschman et al. 2017; Shi et al. 2021). In addition, CCL20LD has previously been shown to be as effective as IL-17A monoclonal antibody therapy in treating mouse models of arthritis and psoriasis (Shi et al. 2021). Among CCR6-targeting agents, only one other compound, PF-07054894, a squaramide-based small-molecule CCR6 antagonist, has been extensively studied and has entered early-phase clinical trials for patients with ulcerative colitis (NCT04388878, NCT05549323 (Li et al. 2023)(;Chinigo et al. 2024). To advance CCL20LD as a biopharmaceutical lead compound, additional safety testing is necessary, particularly regarding its effects on gastrointestinal immunity. In a prior report we used a CCL20LD-specific ELISA to track CCL20LD plasma levels over time and enhance the understanding of CCL20LD pharmacokinetics (Wu et al. 2023). While the completed studies interrogated systemic effects of CCL20LD, its potential impacts in the mucosal immune system, as implicated from CCR6-deficient mice, have yet to be examined. Studies of CCR6 knockout mice indicate the receptor plays an essential role in Peyer’s patch formation (McDonald et al. 2007), exhibiting impaired humoral responses to orally administered antigens (Cook et al. 2000). Given CCR6s expression on Th17 cells, it may prove beneficial to examine the degree of CCL20LD immune modulation alongside monoclonal antibody therapies targeting IL-12, IL-17, and IL-23 (Bai et al. 2019; Ru et al. 2021; Wang et al. 2023). Overall, these preclinical safety studies of CCL20LD indicate a wide therapeutic window with minimal adverse effects even at doses far exceeding those required for therapeutic efficacy. The safety testing of CCL20LD was performed in mice following guidelines for biologic molecules from the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use M3 (ICHM3) and ICHS6 (Prior et al. 2020). These data support the continuation of safety testing in a non-rodent, investigational new drug enabling species to target a signaling axis implicated in autoimmune, inflammatory, and infectious diseases for which therapeutic options remain limited. Injection site scabbing was the only side effect observed at therapeutically relevant doses while higher doses led to extramedullary hematopoiesis, a side effect previously observed with CXCR4 or CXCR1/2 chemokine receptor inhibitors (Prajapati et al. 2023). At elevated concentrations of CCL20LD, immune dysregulation, including lymphocytosis and neutrophilia, was observed, which may correspond with increase susceptibility to viral infections. Despite these findings, the absence of significant clinical toxicity at relevant doses, even those well above the therapeutic concentration, highlights the broad safety of CCL20LD. Methods Recombinant engineered chemokine CCL20LD was provided by XLock Biosciences, Inc., Milwaukee, WI and was expressed and purified as previously described (Getschman et al. 2017). Protein purity was determined by mass spectrometry, and biologic function was confirmed by the inhibition of wild-type CCL20–dependent migration of CCR6-transfected Jurkat cells (RRID:CVCL_U617) in a Transwell chemotaxis assay prior to in vivo experiments. Animal use protocols Male and female Crl:CD1 (RRID:IMSR_CRL:022) 10-week-old mice were used for the systemic observation and clinical chemistry experiments conducted under contract by Charles River Laboratories (Wilmington, MA). Male mice were individually housed, and females were pair-housed when possible. Injections of vehicle PBS or 2.5, 7.5, or 22.5 mg/kg/day of CCL20LD were injected subcutaneously in the scapular region of the back. Animal studies performed at the Medical College of Wisconsin were approved by the Institutional Animal Care and Use Committees at the Medical College of Wisconsin (AUA000076). Male C57BL/6 mice (RRID:IMSR_JAX:000664) were purchased from the Jackson Laboratory (Bar Harbor, ME). Mice were monitored twice per day and weighed prior to the start of the experiment and then once weekly during the experiment. If an animal was determined to be in overt pain/distress beyond the point where recovery seemed reasonable, the animal was humanely euthanized in accordance with the American Veterinary Medical Association Guidelines on Euthanasia. Injection site scabbing analysis Scab formation was documented daily by Charles River Laboratories for all mice, doses, and days. A scab located on the upper dorsal or scapular regions was counted as an injection site scab. A multiple linear regression was then used to analyze the data with day and dose as continuous variables for the main effects along with day-dose as a two-way interaction. To compare sex as a variable, sex was added to the analysis with day-dose kept as a two-way interaction. Clinical pathology sample collection Clinical pathology was performed by Charles River Laboratories. Blood was collected from the mice from their vena cava after carbon dioxide inhalation on day 15. About 0.5 mL of blood was collected in K2-EDTA coated tubes for hematology analysis, while the maximum obtainable amount of blood was collected for clinical chemistry analysis and was separated using a serum gel separator. The order of bleeding was alternated (one animal per sex from each dose group) to reduce handling and time biases. Half of the mice per group had samples analyzed for hematology evaluation while half of the mice per group had samples analyzed for clinical chemistry due to the amount of sample required per test. The mice in each group were randomized. Urine was collected from the animals for a period of at least 12 h. Hematology analysis was performed on the Siemens Advia 2120i Hematology System (RRID:SCR_019337). Clinical chemistry analysis was performed on the Beckman Coulter AU5800 (RRID:SCR_019616). Urine analysis was performed on the Clinitek Novus. Necropsy Necropsy was performed by Charles River Laboratories (RRID:SCR_003792). Animals were subjected to a complete necropsy examination, which included evaluation of the carcass and musculoskeletal system, all external surfaces and orifices, cranial cavity and external surfaces of the brain, and the thoracic, abdominal, and pelvic cavities and their associated organs and tissues. Veterinary pathologists were consulted when needed. All animals were carefully examined for external abnormalities including palpable masses. Organ weight ratios were calculated relative to body and brain weights. Serum cytokine analysis About 100 μL of blood was collected from mice at the designated time points by cheek poke. Blood was collected into a 1.5 mL microcentrifuge tube (VWR, cat. no. 490004–444). The blood was centrifuged at 12,000 × g and the top serum layer collected and stored at −80°C until shipment to Eve Technologies for multiplexed measurement of serum cytokine levels (Calgary, Canada, cat. no. MD44). Bone marrow and spleen processing and flow cytometry analysis Six-week-old male C57BL/6J mice were randomly assigned to treatment or control groups. Mice were given either vehicle PBS, 100 μg CCL20LD, or 200 μg CCL20LD every other day by intraperitoneal injection for 21 days. On day 21, mice were euthanized by carbon dioxide inhalation followed by cervical dislocation. Spleens were collected, mechanically disrupted, and centrifuged at 300 × g for five minutes. The splenocytes underwent red blood cell lysis (eBioscience Labs, Englewood, CO, cat. no. 00–4300-54), a wash with PBS, and then filtered through a 70 μm filter (Millipore, Sigma, Falcon cat. no. 352350). Femur and tibia were used to collect bone marrow. Both bones were cleaned and then flushed with PBS using a 1 mL syringe (Becton Dickinson, Franklin Lakes, NJ, cat. no. 309628) and a 25G needle (Becton Dickinson, cat. no. 305122) to collect contents. The contents were washed and then filtered through a 70 μm filter. For both spleen and bone marrow, 1 × 106 cells were stained with the antibodies listed in Supplementary Table 2 following a Fc block (Biolegend Inc., San Diego, CA, cat. no. 156604, RRID:AB_2783138). Up to 500,000 events were analyzed using a Cytek Aurora (RRID:SCR_019826) multispectral flow cytometer. Flow cytometry data were normalized to total CD45 + events per sample for lineage distribution analysis, and to total CD4 + or CD8 + events for subset analyses of naïve, effector, and central memory T cell populations. Bone marrow progenitor cells were normalized to Lineage negative cells while Lineage negative cells were normalized to total live cells. Flow cytometry data was analyzed using FlowJo v10 (RRID:SCR_008520). Single-cell library preparation Single cell splenocyte suspensions were prepared as described above. CCL20LD treated samples were processed with the Chromium Next Gem (Flex) kit (10X Genomics, Pleasanton, CA) while vehicle treated samples were processed with the Chromium Single Cell 3′ Reagent Kits (v3) kit (10X Genomics). Flex samples were processed following user guide CG000527 using the Chromium Fixed RNA Kit for the mouse transcriptome (cat. no. 1000496) with sample multiplexing. The v3 libraries were prepared using the Chromium Next GEM Single Cell 3’ Kit v3.1 (cat. No. 1000268) with sample multiplexing and libraries were generated and sequenced from the cDNA and 10X Barcodes. Single-cell RNA sequencing and data processing DNA libraries were analyzed using the Illumina NovaSeq X (RRID:SCR_024569) system to achieve roughly 500 million paired end reads per batch. Sequencing results were de-multiplexed and converted to FASTQ using Illumina bcl2fastq (RRID:SCR_015058) software. The 10X Genomics Cell Ranger 8.0.0 software (RRID:SCR_023221) suite (Zheng et al. 2017) was used to perform sample de-multiplexing, barcode processing, and 3’ gene counting. The files were aligned to the GRCm38/mm10 reference genome. Further analysis was performed using R 4.4.3 (RRID:SCR_001905), RStudio (RRID:SCR_000432) 2024.12.1 + 563, and Seurat 5.2.1 (RRID:SCR_016341) (Hao et al. 2024). Raw data were filtered to remove cells with less than 200 detectable genes and an upper limit of detectable genes that ranged from 3500–6000 to remove doublets. The range in detectable genes was due to differences in the chemistry used. Apoptotic cells were filtered by removing cells with > 10% of genes coming from mitochondrial genes. The data were then merged, normalized to the total expression, multiplied by a scaling factor of 10,000, and log-transformed using the NormalizeData() command. Variable features were noted, the data scaled, and a principle component analysis completed prior to sample integration using Harmony (RRID:SCR_022206) (Korsunsky et al. 2019). Harmony was chosen for its focus on batch effect removal over bio-conservation, making it suitable for our data with a large batch effect reflecting the two different chemistries but lower biological variance (Luecken et al. 2022). Cell identification and clustering In total, 15,827 filtered cells were used for analysis. Cells were clustered using a resolution of 0.2. The markers used to identify the main clusters can be seen in Supplementary Fig. 10A and the markers used to identify the B cell subsets can be seen in Supplementary Fig. 10B. Differential gene expression and gene ontology terms Differential gene expression used for the initial cell clustering was analyzed using the Wilcoxon rank-sum test with Bonferroni correction that is included in Seurat’s FindAllMarkers function. Comparisons between control and treated cells were made by pseudobulk using DESeq2 (RRID:SCR_015687) (Love et al. 2014) clusterProfiler (RRID:SCR_016884) (Yu et al. 2012) was used to generate gene ontology terms related to biological processes (Gene Ontology et al. 2023). The EnhancedVolcano package (RRID:SCR_018931) was used to generate volcano plots. Statistical analyses The data was analyzed using GraphPad Prism v10 (RRID:SCR_002798). Statistical analyses included the Student’s unpaired T-test, multiple logistical regression, and one-way ANOVA with Tukey’s multiple comparisons test. Individual statistical tests used are denoted in the figure legends. Supplementary Information Below is the link to the electronic supplementary material. Supplementary file1 (PDF 657 KB) Acknowledgements We thank Galina Petrova, PhD for her guidance and training in the Medical College of Wisconsin’s Children’s Research Institute Flow Cytometry Shared Resource. This research was completed in part with computational resources and technical support provided by the Research Computing Center at the Medical College of Wisconsin. Author contributions Conceptualization: DD, MBD Data curation: DD, DM Formal Analysis: DD Funding acquisition: MBD, BFV, FCP, WFC Investigation: DD, MP, DM Methodology: DD, MBD Project Administration: MBD Resources: FCP, MBD Software: Supervision: MBD Validation: DD, DM Visualization: DD Writing – original draft: DD Writing – review and editing: DD, MP, MD, WFC, STH, FCP, BFV, MBD. Funding This work was supported in part by a Small Business Innovation Research grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) R44 AR081754 to XLock Biosciences, Inc. DD is a member of the Medical Scientist Training Program at the Medical College of Wisconsin, which is supported in part by National Institutes of Health Training Grant T32 GM080202 from the National Institute of General Medical Sciences. DD is supported in part by the grant from the National Cancer Institute F30 CA291095. The content is solely the responsibility of the author(s) and does not necessarily represent the official views of the NIH. Data availability This study did not generate new unique reagents. Single-cell RNA sequencing files were deposited at the Mendeley Data and are available at the DOI http://dx.doi.org/10.17632/s6jwhkxn8c.1. Analytical code is available at https://github.com/The-Michael-Dwinell-Lab-at-MCW/CCL20LD-Safety-and-Efficacy/tree/main Declarations Ethical approval Preclinical experimental procedures involving animals were conducted in accordance with the NIH Guide for the Care and Use of Laboratory Animals and were formally reviewed and approved by the Medical College of Wisconsin Institutional Animal Care and Use Committee (IACUC) (approval No. AUA000076). Ethics statement and patient consent The studies completed solely utilize preclinical approaches. Competing interests MBD, BFV, FCP, STH, WFC have financial interests in Protein Foundry, LLC and XLock Biosciences, Inc which produced CCL20LD. The remaining authors have no conflicts to disclose. Footnotes Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Supplementary file1 (PDF 657 KB) Data Availability Statement This study did not generate new unique reagents. Single-cell RNA sequencing files were deposited at the Mendeley Data and are available at the DOI http://dx.doi.org/10.17632/s6jwhkxn8c.1. Analytical code is available at https://github.com/The-Michael-Dwinell-Lab-at-MCW/CCL20LD-Safety-and-Efficacy/tree/main